Export file:


  • RIS(for EndNote,Reference Manager,ProCite)
  • BibTex
  • Text


  • Citation Only
  • Citation and Abstract

Neuroenhancement and the Developing Brain: Commentary on the AIMS Neuroscience Special Issue on “Neuroenhancers”

1. Neuroscience Graduate Group, University of Pennsylvania, Philadelphia, Pennsylvania;
2. Center for Sleep and Circadian Neurobiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania

Topical Section: Neuroenhancement

The use of pharmaceutical neuroenhancers to improve cognitive function poses unique neurobiological concerns as stimulants are being widely prescribed to adolescents and young adults with increasing prevalence. In the following commentary on the papers by Hoffman et al [1] and Cheung and Pierre [2] in the special issue on Neuroenhancers, we discuss the need to consider the effects of stimulant use in healthy adolescents. We review some of the data that has emerged on the neurobiological and behavioral effects of adolescent neuroenhancement, and conclude that special consideration should be taken to characterize the consequences of neuroenhancement use in the developing brain. Studies focused specifically on adolescent vulnerabilities to neuroenhancement are necessary because the brain undergoes dynamics changes that are unique to this period of development, which differentiates it from the healthy adult response to neuroenhancer exposure. Moving forward, scientists and physicians should take careful consideration to examine the long-term neurological consequences of neuroenhancers so that the therapeutic benefits that might be gained from neuroenhancement are not shadowed by negative consequences to public health in the future.
  Article Metrics

Citation: Sarah Ly, Nirinjini Naidoo. Neuroenhancement and the Developing Brain: Commentary on the AIMS Neuroscience Special Issue on “Neuroenhancers”. AIMS Neuroscience, 2015, 2(4): 229-235. doi: 10.3934/Neuroscience.2015.4.229


  • 1. Hofmann SG, Mundy EA, Curtiss J (2015) Neuroenhancement of exposure therapy in anxiety disorders. AIMS Neurosci 2: 123-138.    
  • 2. Cheung EH, Pierre JM (2015) The medical ethics of cognitive neuroenhancement. AIMS Neurosci 2: 102-122.
  • 3. Beyerstein B (1999) Whence cometh the myth that we only use ten percent of our brain? In Della Sala S (Ed), Mind Myths: Exploring Popular Assumptions about the Mind and Brain. New York, NY: J. Wiley & Sons, 314-335.
  • 4. Maher B (2008) Poll results: look who's doping. Nature 452: 674-675.    
  • 5. Franke AG, Bagusat C, Rust S, et al. (2014) Substances used and prevalence rates of pharmacological cognitive enhancement among healthy subjects. Eur Arch Psychiatry Clin Neurosci 264: S83-S90.
  • 6. Singh I, Bard I, Jackson J (2014) Robust resilience and substantial interest: a survey of pharmacological cognitive enhancement among university students in the UK and Ireland. PLoS One 9: e105969.    
  • 7. Bagot KS, Kaminer Y (2014) Efficacy of stimulants for cognitive enhancement in non-attention deficit hyperactivity disorder youth: a systematic review. Addiction 109: 547-557.    
  • 8. Smith ME, Farah MJ (2011) Are prescription stimulants "smart pills"? The epidemiology and cognitive neuroscience of prescription stimulant use by normal healthy individuals. Psychol Bul 137: 717-741.
  • 9. Greenhill LL, Pliszka S, Dulcan MK, et al. (2002) Practice parameter for the use of stimulant medications in the treatment of children, adolescents, and adults. J Am Acad Child Adolesc Psychiatry 41: 26S-49S.    
  • 10. Chai G, Governale L, McMahon AW, et al. (2012) Trends of outpatient prescription drug utilization in US children, 2002-2010. Pediatrics 130: 23-31.
  • 11. Fuhrmann D, Knoll LJ, Blakemore SJ (2015) Adolescence as a sensitive period of brain development. Trends Cogn Sci: S1364-6613(15)00172-2.
  • 12. Gogtay N, Giedd JN, Lusk L, et al. (2004) Dynamic mapping of human cortical development during childhood through early adulthood. Proc Natl Acad Sci U. S. A. 101: 8174-8179.    
  • 13. Harris JJ, Reynell C, Attwell D (2011) The physiology of developmental changes in BOLD functional imaging signals. Dev Cogn Neurosci 1: 199-216.    
  • 14. Setlik J, Bond GR, Ho M (2009) Adolescent prescription ADHD medication abuse is rising along with prescriptions for these medications. Pediatrics 124: 875-880.    
  • 15. Akinbami LJ, Liu X, Pastor PN, et al. (2011) Attention deficit hyperactivity disorder among children aged 5-17 years in the United States, 1998-2009. NCHS Data Brief : 1-8.
  • 16. Arria AM, Wish ED (2006) Nonmedical use of prescription stimulants among students. Pediatric Annals 35: 565-571.    
  • 17. Wu LT, Pilowsky DJ, Schlenger WE, et al. (2007) misuse of methamphetamine and prescription stimulants among youths and young adults in the community. Drug Alcohol Depend 89: 195-205.    
  • 18. Arria AM, DuPont RL (2010) Nonmedical prescription stimulant use among college students: why we need to do something and what we need to do. J Addict Dis 29: 417-426.
  • 19. Garnier-Dykstra LM, Caldeira KM, Vincent KB, et al. (2012) Nonmedical use of prescription stimulants during college: four-year trends in exposure opportunity, use, motives, and sources. J Am Coll Health 60: 226-234.
  • 20. McCabe SE, West BT, Teter CJ, et al. (2014) Trends in medical use, diversion, and nonmedical use of prescription medications among college students from 2003 to 2013: Connecting the dots. Addict Behav 39: 1176-1182.    
  • 21. Zosel A, Bartelson BB, Bailey E, et al. (2013) Characterization of adolescent prescription drug abuse and misuse using the researched abuse diversion and addiction-related surveillance (RADARS®) system. J Am Acad Child Adolesc Psychiatry 52: 196-204.    
  • 22. DeSantis AD, Webb EM, Noar SM (2008) Illicit use of prescription ADHD medications on a college campus: a multimethodological approach. J Am Coll Health 57: 315-324.    
  • 23. Sepúlveda DR, Thomas LM, McCabe SE, et al. (2011) Misuse of prescribed stimulant medication for ADHD and associated patterns of substance use: preliminary analysis among college students. J Pharm Pract 24: 551-560.    
  • 24. Hildt E, Lieb K, Bagusat C, et al. (2015) Reflections on addiction in students using stimulants for neuroenhancement: A preliminary interview study. Biomed Res Int: 621075.
  • 25. van der Marel K, Klomp A, Meerhoff GF, et al. (2014) Long-term oral methylphenidate treatment in adolescent and adult rats: differential effects on brain morphology and function. Neuropsychopharmacology 39: 263-273.
  • 26. van der Marel K, Bouet V, Meerhoff GF, et al. (2015) Effects of long-term methylphenidate treatment in adolescent and adult rats on hippocampal shape, functional connectivity and adult neurogenesis. Neuroscience. S0306-4522(15)00385-1.
  • 27. Burgos H, Cofré C, Hernández A, et al. (2015) Methylphenidate has long-lasting metaplastic effects in the prefrontal cortex of adolescent rats. Behav Brain Res 291: 112-117.
  • 28. Rowan JD, McCarty MK, Kundey SM, et al. (2015) Adolescent exposure to methylphenidate impairs serial pattern learning in the serial multiple choice (SMC) task in adult rats. Neurotoxicol Teratol 51: 21-26.
  • 29. Shanks RA, Ross JM, Doyle HH, et al. (2015) Adolescent exposure to cocaine, amphetamine, and methylphenidate cross-sensitizes adults to methamphetamine with drug- and sex-specific effects. Behav Brain Res 281: 116-124.    
  • 30. Wolpe PR (2002) The neuroscience revolution. Hastings Cent Rep 32: 8.
  • 31. Andersen SL, Navalta CP (2004) Altering the course of neurodevelopment: a framework for understanding the enduring effects of psychotropic drugs. Int J Dev Neurosci 22: 423-440.


Reader Comments

your name: *   your email: *  

Copyright Info: 2015, Sarah Ly, et al., licensee AIMS Press. This is an open access article distributed under the terms of the Creative Commons Attribution Licese (http://creativecommons.org/licenses/by/4.0)

Download full text in PDF

Export Citation

Copyright © AIMS Press All Rights Reserved